Lakefront Biotherapeutics N.V. (LKFT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | - | - | - | - | - | 1,112 | 991 | - |
| Operating profit | €m | 501 | 610 | ||||||
| Net profit | €m | - | - | - | - | - | 321 | 597 | - |
| EPS reported | € | 4.87 | 9.05 | ||||||
| Operating cashflow per share | € | -3.91 | -2.75 | ||||||
| Capex per share | € | 0.21 | 0.07 | ||||||
| FCF per share | € | -4.12 | -2.82 | ||||||
| Free cash flow | €m | -271 | -197 | ||||||
| Net debt | €m | -2,998 | -2,982 | ||||||
| Book value equity | €m | 3,236 | 3,253 | ||||||
| Book value per share | € | 49.10 | 46.46 | ||||||
| Number of shares | m | 65.9 | 70.03 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 2.68 | ||||||
| P/B LTM | x | 0.57 | 0.56 | ||||||
| P/S LTM | x | 1.65 | 1.85 | ||||||
| P/FCF LTM | x | -6.76 | -9.29 | ||||||
| EV/EBITDA LTM | x | 4.88 | 3.30 | ||||||
| EV/Sales LTM | x | 1.58 | 1.58 | ||||||
| Earnings Yield LTM | % | +17.50% | +37.31% | ||||||
| FCF Yield | % | -14.79% | -10.76% | ||||||
| Quality | |||||||||
| ROE | % | +9.92% | +19.58% | ||||||
| ROIC | % | +15.40% | 0.00% | ||||||
| Operating margin | % | +45.08% | +61.57% | ||||||
| Gross margin | % | +97.33% | +94.88% | ||||||
| FCF/Sales | % | -24.39% | -19.93% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -39.24 | - | ||||||
| Net Debt/EBITDA | x | -0.23 | 0.00 | ||||||
| EBIT/Net interest | x | 226.16 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.93 | -0.92 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lakefront Biotherapeutics N.V. (LKFT)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free